Newer antidepressants and the discontinuation syndrome

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 7, 1997, Pages 17-22

  Haddad, Peter ^a  

^a Prestwich Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGGRESSIVENESS; CLINICAL FEATURE; DEPRESSION; DRUG MONITORING; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IMPULSIVENESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; VERTIGO; WITHDRAWAL SYNDROME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CYCLOHEXANOLS; DIZZINESS; FLUOXETINE; HEADACHE; HUMANS; INCIDENCE; NAUSEA; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SLEEP STAGES; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME;

EID: 0030875050     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Mann AM, MacPherson AS. Clinical experience with imipramine (G22355) in the treatment of depression. Canadian Psychiatric Association Journal 1959;4:38-47
2. Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Int Clin Psychopharmacol 1987;2:1-19
3. Dilsaver SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychopharmacol 1987;7:1-10
4. Dilsaver SC, Feinberg M, Greden JF. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983;140:249-251
5. Dilsaver SC, Greden JF. Antidepressant withdrawal syndromes: evidence for supersensitivity of the cholinergic system as an etiologic factor [letter]. J Clin Psychopharmacol 1983;3:330
6. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry 1984;19:237-256
7. Dilsaver SC, Kronfol Z, Greden JF, et al. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983;3:157-164
8. Dilsaver SC. Withdrawal mechanisms associated with antidepressant and amipsychotic agents. Drug Safety 1994;10:103-114
9. Pacheco L, Malo P, Aragues E, et al. More cases of paroxetine withdrawal syndrome [letter]. Br J Psychiatry 1996;169:384
10. Committee on Safety of Medicines. Dystonia and withdrawal symptoms with paroxetine (Seroxat). Current Problems in Pharmacovigilance 1993; 19:1
11. Adverse Drug Reactions Advisory Committee. Australian Adverse Drug Reactions Bulletin 1996;15:3
12. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors, including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757-763
13. Gillespie C, Wildgust H, Haddad P, et al. SSRIs and withdrawal syndrome. In: Proceedings of the 10th World Congress of Psychiatry 1996; Aug 23-28,1996; Madrid, Spain. Abstract G2389
14. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
15. Bhaumik S, Wildgust HJ. Letter. Human Psychopharmacol 1996;11: 337-338
16. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-149
17. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
18. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol 1994;14:206-207
19. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome [letter] Biol Psychiatry 1993;33:851-852
20. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
21. Young AH, Currie A, Ashton CH. Antidepressant withdrawal syndrome [letter]. Br J Psychiatry 1997;170:288
22. Kramer JD, Klein DF, Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961;118:549-550
23. Bialos D, Giller E, Jatlow P, et al. Recurrence of depression after discontinuation of amitriptyline. Am J Psychiatry 1982;139:325-329
24. Diamond BI, Borison RL, Katz R, et al. Rebound reactions due to clomipramine. Psychopharmacol Bull 1989;255:209-212
25. Tyrer P. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment. J Affect Disord 1984;6:1-7
26. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991;148:1263
27. Einbinder E. Fluoxetine withdrawal? [letter] Am J Psychiatry 1995;152: 1235
28. Ellison JM. SSRI withdrawal buzz [letter]. Am J Psychiatry 1993;55: 544-545
29. Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry 1995;152:810
30. Szabadi E. Fluvoxamine withdrawal syndrome [letter]. Br J Psychiatry 1992;160:283-284
31. Bloch M, Stager SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995;346:57
32. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54(9, suppl):14-34
33. Richelson E. Pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(9, suppl):34-41
34. Farah A, Lauer T. Possible venlafaxine withdrawal syndrome [letter]. Am J Psychiatry 1996;153:576
35. Louie AK, Lannon RA, Kirsch MA, et al. Venlafaxine withdrawal reactions [letter]. Am J Psychiatry 1996;153:1652
36. Benazzi F. Venlafaxine withdrawal symptoms [letter]. Can J Psychiatry 1996;41:487